ArticleStroke (Hoboken, N.J.)2023
Half-Dose (45 mg Twice Daily) Ticagrelor Versus Clopidogrel in Neuroendovascular Dual Antiplatelet Therapy: A Single-Center Cohort Study.
Article in Stroke (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Half-dose ticagrelor versus clopidogrel dual antiplatelet therapy in flow diverter-treated intracranial aneurysms: analysis of platelet reactivity and perioperative safety outcomes.Acta neurochirurgica · 2026Article
- Intracranial hemorrhagic events associated with flow diversion treatment: a retrospective analysis from a single academic institution.Neurosurgical review · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular literature has found aspirin-based dual antiplatelet therapy using half-dose ticagrelor (45 mg BID [T45]) to be superior to standard-dose clopidogrel (75 mg once daily) in achieving lower P2Y12 reaction units without resulting in an increased incidence of intracranial hemorrhage. We present the first neuroendovascular experience based on T45 versus standard-dose clopidogrel dual antiplatelet therapy in patients undergoing stent-assist coiling/flow diversion as treatment for unruptured intracranial aneurysms. Methods: This was a retrospective cohort study comparing patients receiving dual antiplatelet therapy with T45+aspirin 81 mg daily (group 1) with those receiving standard-dose clopidogrel+aspirin 325 mg daily (group 2). The primary outcome was ischemic stroke occurring intraoperatively or within 48 hours postoperatively. The secondary outcomes were delayed ischemic stroke, intracranial hemorrhage, and 6-month angiographic result. Results: A total of 111 patients met the final inclusion criteria: group 1/T45 (37.8%, n=42) and group 2/standard-dose clopidogrel (62.2%, n=69). The median (interquartile range) P2Y12 reaction units was significantly lower in group 1 (69; 37-124) versus group 2 (135; 75.5-175.5; Conclusions: T45-based dual antiplatelet therapy may be feasible in neuroendovascular interventions with comparable ischemic and hemorrhagic outcomes. This hypothesis needs to be further explored in larger prospective clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.